2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
3216
Carcinoma, Non-Small-Cell Lung
2729
Breast Neoplasms
2551
Colorectal Neoplasms
1463
Prostatic Neoplasms
1307
Neoplasm Metastasis
1301
Multiple Myeloma
1112
Melanoma
1103
Ovarian Neoplasms
1006
Lung Neoplasms
945
Recurrence
924
Leukemia, Myeloid, Acute
879
Pancreatic Neoplasms
833
Lymphoma, Non-Hodgkin
767
Lymphoma
713
Stomach Neoplasms
692
Carcinoma, Renal Cell
660
Carcinoma, Hepatocellular
647
Leukemia, Lymphocytic, Chronic, B-Cell
560
Squamous Cell Carcinoma of Head and Neck
550
Lymphoma, Follicular
515
Head and Neck Neoplasms
490
Glioblastoma
473
Small Cell Lung Carcinoma
447
Lymphoma, Large B-Cell, Diffuse
440
Triple Negative Breast Neoplasms
436
Advanced Solid Tumors
432
Leukemia
426
Uterine Cervical Neoplasms
420
Urinary Bladder Neoplasms
405
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts